Jaguar Health Provides Crofelemer for Pediatric Intestinal Failure Treatment

Jaguar Health, through Napo Pharmaceuticals, is offering crofelemer powder for oral solution in two FDA-approved expanded access programs. These programs target pediatric intestinal failure patients suffering from microvillus inclusion disease (MVID), an ultrarare condition. The novel crofelemer formulation is being utilized under separate Single-Patient Investigational New Drug (sIND) applications in the United States.

Initial results presented at the ELITE PED-GI Congress indicated a reduction in total parenteral nutrition (TPN) needs in MVID and short bowel syndrome with intestinal failure (SBS-IF) patients, heralding potential improvements in these challenging conditions. Further proof-of-concept results are anticipated later this year, providing more data on crofelemer's safety and efficacy.